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Summary
Objective: The presence of YKL-40 (human cartilage glycoprotein 39) in synovium, cartilage and synovial fluid (SF) from knee joints of
patients with rheumatoid arthritis and osteoarthritis (OA) were related to histopathological changes in synovium and cartilage and to serum
YKL-40 and other biochemical markers.
Methods: The localization of YKL-40 in synovium and cartilage was determined by immunohistochemistry. Synovial inflammation was
estimated histologically and by magnetic resonance imaging (MRI). Biochemical markers of inflammation, neutrophil activation and cartilage
metabolism were analysed. YKL-40 concentrations in serum and SF were determined by RIA and ELISA.
Results: In the synovium YKL-40 positive cells were found in lining and stromal cells (macrophages) and the number of YKL-40 positive cells
was related to the degree of synovitis. In arthritic cartilage, YKL-40 was located to chondrocytes. YKL-40 levels in SF were higher in RA
patients with moderate/severe or none/slight synovitis of the knee joint compared to OA patients with moderate/severe or none/slight
synovitis. SF YKL-40 correlated with the synovial membrane and the joint effusion volumes determined by magnetic resonance imaging
(MRI) and with other biochemical markers of intercellular matrix metabolism. SF YKL-40 was higher than serum YKL-40, and a relationship
existed between the YKL-40 levels in SF and serum. Intraarticular glucocorticoid injection was followed by clinical remission and a decrease
in serum YKL-40, which increased again at clinical relapse.
Conclusions: YKL-40 in SF is derived from cells in the inflamed synovium, chondrocytes and SF neutrophils. Joint derived YKL-40 influences
serum YKL-40. YKL-40 may be involved in the pathophysiology of the arthritic processes and reflect local disease activity. © 2001
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*YKL-40 is also named human cartilage glycoprotein-39 (HC
gp-39) (Ref. 1), 38-kDa heparin binding glycoprotein (Ref. 4), and
CHI3L1 (Ref. 7). The protein had been termed YKL-40 from its
molecular weight (40 kDa) and the one letter code for its three
NH2-terminal amino acids (tyrosine, lysine, and leucine) (Ref. 18).Introduction
YKL-40*, also called human cartilage glycoprotein-39 (HC
gp-39)1, is a mammalian member of family 18 glycosyl
hydrolases1–8 and has a known gene sequence7. YKL-40203is a heparin and chitin-binding lectin4,8 without chitinase
activity1,5,8. The physiological function of YKL-40 is
unknown, but the protein contains several DR4 peptide
binding motifs and may be a target of the immune response
in rheumatoid arthritis (RA)9. Several cells present in the
arthritic joint can secrete YKL-40. It is one of the most
abundant proteins secreted in vitro by chondrocytes1,5 and
synovial cells2 from patients with RA. We have recently
reported a high number of YKL-40 positive chondrocytes in
articular cartilage from the hip joint of patients with osteo-
arthritis (OA)10. YKL-40 positive chondrocytes were in
particular located in the superficial and middle layer of the
cartilage and especially in areas of the joint with a consider-
able biomechanical load. Chondrocytes from normal carti-
lage were mainly YKL-40 negative10. Another recent
study11 demonstrated by in-situ hybridization the same
zonal distribution of YKL-40 (HC gp-39) in osteoarthritic
cartilage, as well as the absence of the protein in normal
cartilage. YKL-40 expression by osteophytic tissue in end
stage osteoblasts and by primary osteocytes from osteoar-
thritic patients was also reported11. YKL-40 is not produced
by normal monocytes but is secreted by differentiated
and activated human macrophages in many different
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The investigation included a cross-sectional and a longi-
tudinal study. The knee joint was used as a model and
dominating knee joint involvement was an inclusion criteria.
The research protocols were approved by the Ethics
Committee for Medical Research in Copenhagen. In
accordance with the Helsinki Declaration II each patient
was informed about the study verbally and in writing, and all
gave their written consent.CROSS SECTIONAL STUDY
Twenty patients with RA and 39 patients with OA were
included. The patients were scheduled to undergo total
knee joint replacement [RA (N=13) and OA (N=39)] or
arthroscopic synovectomy of the knee joints [RA (N=7)].
The patients fulfilled the American College of Rheumatol-
ogy 1987 classification criteria for RA19 or the ACR 1986
classification criteria for idiopathic OA of the knee20.
Patients with malignant disease or elevated liver enzymes
were not included. Seven of the patients with RA were
treated with slow-acting antirheumatic drugs (DMARDs)
[methotrexate (N=2), sulfasalazine (N=4), penicillamine
(N=1)], either as the only treatment (N=4), in combination
with non-steroidal antiinflammatory drugs (NSAIDs) (N=1),
or in combination with low dose oral prednisolone (N=2).
Low dose oral prednisolone (1.25–10.0 mg/day) was given
as the only treatment in six patients, and given in combi-
nation with NSAID in three patients. Twelve patients were
treated with NSAID alone [RA (N=1) and OA (N=11)].
Three patients with RA did not receive any kind of antirheu-
matic medicine. Just prior to surgery a clinical examination
and blood samples were performed. In case of joint effusion
synovial fluid was aspirated by the surgeon when the
operation was initiated. Variable amounts of synovial fluid
were collected dependent upon the amount available in the
joint and the degree of waste in connection with thecollection. Thirty-one of these patients underwent a MRI
determination of the knee joint and were included in a
project investigating MRI determination of synovial mem-
brane and joint effusion volumes in relation to signs of
synovial inflammation21.LONGITUDINAL STUDY
Eighteen patients with RA according to the ACR 1987
classification criteria19 and clinical signs of knee joint
synovitis (15 females and three males) were included.
Median disease duration was 5.5 years (range 0.3–36
years) and duration of knee symptoms was 0.6 years
(range 0.1–7 years). The patients had a clinical indication
for arthrocentesis and intraarticular corticosteroid injection.
During arthrocentesis, as much synovial fluid as possible
was aspirated, and 80 mg methylprednisolone acetate
(2 ml, 40 mg/ml) plus 6 ml lidocaine 0.5% (lidocaine hydro-
chloride 5 mg/ml) were injected into the knee joint. Serum
samples were collected just prior to corticosteroid injection
and after 1, 7, 14, 30, 60, 90 and 180 days. Seven patients
received continuous therapy with low-dose oral pred-
nisolone (2.5–8.75 mg/day) in combination with DMARD
(sulfasalazine (N=2) and methotrexate (N=1)) and NSAID
(N=3), or with NSAID alone (N=2). Three of the patients
were treated with DMARD [penicillamine (N=2) and
sulfasalazine (N=1)] in combination with NSAID, eight
patients received NSAID alone. No patients had received
intraarticular glucocorticoid therapy within the last 4 weeks.SYNOVIAL MEMBRANE BIOPSIES
From all patients included in the cross-sectional study,
synovial biopsy specimens were obtained during surgery.
In patients who had a MRI determination of the synovial
membrane and joint effusion volume performed, four pre-
selected sites of the synovial membrane of the knee joint21
were chosen. Patients, who did not have a MRI determi-
nation, had synovial membrane biopsies obtained from
three different sites of the knee joint: (1) the lateral; (2) the
medial; and (3) the suprapatellar recess. The surgeon
selected these three biopsies to represent the overall
degree of synovitis of the knee joint [assessed by edema,
volume and vascularity (redness) of the synovial mem-
brane]. The synovial biopsy specimens were immediately
fixed in 10% neutral buffered formalin, pH 7.0 until the next
day, dehydrated in graded mixtures of ethanol and water,
immersed in xylene, paraffin embedded, cut at 5 m and
stained with hematoxylin and eosin.SYNOVIAL MEMBRANE AND JOINT EFFUSION VOLUMES
DETERMINED BY MRI
MRI was performed using a 1.5-Tesla Magnetom
(Siemens, Erlangen, Germany) equipped with a dedicated
knee coil. Synovial membrane and joint effusion volumes
were calculated from continuous pre- and post-gadolinium-
DPTA (Shering, Berlin, Germany) T1-weighted transversal
MR-images, by means of image processing software. The
method is described in detail elsewhere21.HISTOLOGICAL EVALUATION OF SYNOVIAL SPECIMENS
Synovial inflammatory activity was graded under blinded
conditions by an experienced histopathologist. The gradingtissues6–8,12,13, including inflamed synovium from patients
with active RA6. Furthermore, YKL-40 is present in the
specific granules of neutrophils and is exocytosed by
activation14.
YKL-40 in serum and synovial fluid can be measured by
radioimmunoassay (RIA)3 or enzyme linked immuno-
sorbent assay (ELISA)15. Increased levels of YKL-40 in
serum and synovial fluid are found in patients with active
RA3,15–16 or severe knee OA17 compared to normal sub-
jects17. A correlation exits between the level of YKL-40 in
serum and synovial fluid with approximately 10-fold higher
values in synovial fluid3,17.
The object of the present study was to elucidate a
possible involvement of YKL-40 in the pathophysiology of
RA and OA as well as the role of YKL-40 as a marker of
disease activity. The presence of YKL-40 in the synovial
membrane and articular cartilage was examined by
immunohistochemical methods, and the YKL-40 concen-
trations in synovial fluid and serum were examined by
immunoassays (RIA and ELISA) in patients with RA and
OA. We related the YKL-40 findings with histopathological
changes in the synovial membrane and articular cartilage,
with the synovial membrane and the joint effusion volumes
[determined by magnetic resonance imaging (MRI)]
and with biochemical markers of inflammation, neutrophil
activation and cartilage metabolism.
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age of all of the synovial tissue from all the biopsies and
was based upon a grading of the following nine parameters
and described in details elsewhere21:
(1) subsynovial infiltration of polymorphonuclear leuko-
cytes;
(2) subsynovial infiltration of mononuclear leukocytes;
(3) surface fibrin deposition;
(4) multiplication of the synovial lining;
(5) villous hypertrophy of the synovial surface;
(6) proliferation of blood vessels;
(7) perivascular edema;
(8) formation of granulation tissue; and
(9) fibrosis.
Each of the nine parameters was graded as 0 (none), 1
(mild), 2 (moderate), or 3 (severe), and an ‘average grade’
for each parameter was calculated as the average of the
grading of the collected biopsies from each knee. Based
upon a total score for each knee joint achieved from the
average score for all of the nine parameters considered,
the knees were divided into two groups: ‘None/slight’ syno-
vial inflammation (N=40) included knees with an average
grade ≤1 for all signs of inflammatory activity considered;
and ‘moderate/severe’ synovial inflammation (N=19)
included knees with an average grade >1 for all signs of
inflammatory activity considered.IMMUNOHISTOCHEMICAL STAINING FOR YKL-40 ANTIGEN IN
SYNOVIAL MEMBRANE
Alkaline phosphatase staining technique for polyclonal
antibodies was used and included the following steps (all
performed at room temperature and separated by washes
in TBS). Non-specific binding was inhibited by incubation
for 20 min with 3% bovine serum albumin (BSA) (Sigma
A-4503) in Tris buffered saline (TBS, 5 mM Tris-HCl,
146 mM NaCl, pH 7.4). This buffer was used for dilution of
the different antibodies. Incubation for 30 min with an
affinity-purified rabbit polyclonal immunoglobulin (IgG)
against human YKL-40 (IgG concentration of the YKL-40
antibody was 33 g/mL). The human YKL-40 used for
immunization of rabbits and for affinity purification of anti-
bodies is described elsewhere3. The YKL-40 antibody used
in these studies was purified from rabbit antiserum by
affinity chromatography using a Sepharose support with
covalently attached purified human YKL-40. The antibodies
were eluted by 100 mM glycine (pH 2.5). Non-immune
rabbit IgG (DAKO X0936, Copenhagen, Denmark) was
used as negative control in the same IgG concentration
(33 g/mL). Thereafter incubation for 30 min with alkaline
phosphatase-conjugated swine antibodies to rabbit
IgG (DAKO D0306, diluted 1:20). Sigma FASTY
BCIP/NBT tablets (Sigma B-5655; 5-Bromo-4-chloro-3-
indolylphosphate/Nitro Blue Tetrazolium) with 0.25 mg/mL
Levamisole in 0.1 M Tris-HCl, pH 9.5 was used as color
substrate (30 min incubation time). Positive staining was
recognized as a dark blue/violet color.DOUBLE STAINING FOR YKL-40 AND CD68 (MACROPHAGE
PROTEIN) IN THE SYNOVIAL MEMBRANE
Peroxidase/DAB (3.3–diaminobenzidine tetrahydrochlor-
ide (DAB; KemEnTec, Copenhagen, Denmark) was used
as immunostain for the second immunostaining step in thedouble staining procedure, which included the following
sequences (all performed at room temperature and sep-
arated by washes in TBS/Tween20). The sections
were pre-incubated with 0.6% H2O2 (Perhydrol, Merc,
Darmstadt, Germany) in 0.005 M TBS for 30 min, and
staining for YKL-40 antigen was performed as described in
the section above. After incubation with Sigma FASTY
BCIP/NBT the color reaction was stopped in distilled water
at 4°C. Nonspecific binding was inhibited by incubation for
30 min with 3% BSA in TBS (this buffer was also used for
dilution of the various antibodies). Then incubation was
performed for 30 min with mouse antihuman CD68 (DAKO
M814), diluted 1:50, followed by incubation with a rabbit
antimouse IgG (DAKO Z259), diluted 1:20. Non-immune
mouse serum (DAKO X0931) was used as a negative
control in the same IgG concentration. Then incubation was
carried out for 30 min with peroxidase labeled mouse
monoclonal PAP [horseradish peroxidase labeled mouse
monoclonal antihorseradish peroxidase (DAKO P850)].
Pre-incubation for 10 min with DAB (KemEnTec 4170),
0.5 mg/mL buffer, pH 7.0 was followed by incubation for
10 min in the same DAB solution but with the addition of
0.018% H2O2. The reaction was stopped with distilled
water at 4°C for 15 min. Positive staining was recognized
as a dark blue/violet color for YKL-40 antigen and a brown
color for CD68 antigen.MICROSCOPIC EVALUATION OF IMMUNOHISTOCHEMICAL STAINING
OF SYNOVIAL SPECIMENS
The synovial sections were examined blindly two times
by the same observer and scored for the presence of
YKL-40 positive cells in a scale as follows: score 0=all cells
negative; score 1=few cells positive (approximately
1–25%); score 2=a considerable number of cells positive
(approximately 25–75%); score 3=most/all cells positive
(approximately 75–100%).ARTICULAR CARTILAGE BIOPSIES
Standardized samples of cartilage representing all
aspects of the joint surfaces (femoral, tibial and patellar
surface) of the knee were collected from up to 16 topo-
graphically different areas (Fig. 1) from four of the patients
with RA (mean age 63 years, range 34–74) and from four of
the patients with OA (mean age 77 years, range 74–79)
from the cross-sectional study. Only 58 biopsies from the
patients with RA and 59 biopsies from the patients with OA
were collected, because some areas of the joint surfaces
contained only denuded bone. The cartilage samples were
stored in cryovials at −80°C until immunohistochemical
analysis.HISTOLOGICAL EVALUATION OF CARTILAGE SPECIMENS
The cartilage sections were evaluated for the presence
or absence of histopathological cartilage changes, includ-
ing surface fibrillation/fissures and clusters/clones22.IMMUNOHISTOCHEMICAL STAINING FOR YKL-40 ANTIGEN IN
CARTILAGE
Four micrometer cryostat cartilage sections were fixed
with acetone at room temperature for 15 min. Avidin/
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used as described recently10. To assess if the accessibility
of the YKL-40 epitope of the antibody was hindered by
extracellular matrix interactions in the cartilage some of the
sections were treated with either protease, 0.05% (type 14,
Sigma P5147), trypsin, 0.1% (Sigma T8128) or hyaluroni-
dase, 0.1% (Fluka 531712) for 10 min at 37°C prior to
the immunohistochemical staining with an affinity-purified
rabbit polyclonal antiserum against human YKL-40 (IgG
concentration of 33 g/mL) followed by incubation with
biotinylated swine antirabbit IgG (DAKO E0353, diluted
1:400). Antibody binding was visualized by a complex of
avidin-biotinylated horseradish peroxidase (ABComplex/
HRP, DAKO K0355) and AEC (3-amino-9-ethylcarbazole)
staining kit (SIGMA AEC101). Positive staining was a red
color associated with the cytoplasm of the cell.MICROSCOPIC EVALUATION OF IMMUNOHISTOCHEMICAL STAINING
OF CARTILAGE SPECIMENS
Two of the sections [RA (N=1) and OA (N=1)] were not
evaluated due to inadequate quality (tissue folds). The
cartilage sections were examined blindly by two observers
and scored for the presence of YKL-40 positive chondro-
cytes in a scale as follows: score 0=all chondrocytes
negative; score 1=few chondrocytes positive (1–25% posi-
tive); score 2=considerable number of chondrocytes posi-
tive (25–75%); and score 3=most/all chondrocytes positive
(75–100%).BIOCHEMICAL ANALYSIS OF SERUM AND SYNOVIAL FLUID
Blood samples were allowed to clot at room temperature
and then centrifuged at 2000 g for 10 min. Serum was
either analysed immediately or stored at −80°C until analy-
sis was performed. The synovial fluid samples were centri-
fuged at 2000 g for 10 min and the cell-free supernatants
were stored at −80°C until analysis was performed. ESR in
blood was determined by the Westergren method and
serum CRP was determined with nephelometry. YKL-40CLINICAL JOINT ASSESSMENT
Clinical assessment of disease activity in the joints
included assessment of joint swelling and tenderness. The
knee joints as well as the total number of joints involved
were registered. Clinical indication for arthrocentesis of the
knee joint and subsequent intraarticular corticosteroid
injection was determined by clinical signs of intraarticular
fluid and of synovitis. Remission was defined by absence of
synovial swelling and tenderness of the knee joint. Clinical
relapse was defined by recurrence of joint swelling and
tenderness.STATISTICAL ANALYSIS
The statistical analysis was performed with SPSS® (Stat-
istical Package for the Social Science) Software. Results
are given as median, range and ratios. Comparison
between groups was performed by the non-parametric
Mann–Whitney test or the Kruskal–Wallis test (and subse-
quent Dunn’s method). Comparison between two related
samples was performed by the Wilcoxon signed ranks test.
Subsequent comparison between the consecutive changes
over time was performed by regression analysis (random
coefficient regression model) using the ‘Ime’ software by
Pinheiro and Bates. Correlation analysis between the dif-
ferent parameters was calculated by the Spearman rho
test. P-values less than 0.05 were considered significant.Fig. 1. Standardized samples of cartilage were collected from up to
16 topographically different areas of the arthritc knee joint; Tibia:
condylus medialis tibiae: 1=anterior, 2=intermediate, 3=posterior,
4=central; condylus lateralis tibiae: 5=anterior, 6=intermediate,
7=posterior, 8=central; Femur: condylus lateralis femoris:
9=anterior, 10=intermediate, 11=posterior; condylus medialis
femoris: 12=anterior, 13=intermediate, 14=posterior; 15=facies
patellaris femoris; Patella: 16=facies articularis patellae.Results
The clinical characteristics of the patients are shown in
Table I. Patients with RA had more swollen joints, a higher
histological score of synovial inflammation and a larger
volume of synovial membrane of the knee joint (determined
by MRI) than patients with OA. ESR, serum CRP, serum
and synovial fluid YKL-40 and PIIINP were highest in
patients with RA. Serum YKL-40 levels were higher in RA
patients compared to healthy subjects (median 296 g/L vs
102 g/L, P<0.01) (Table I). No differences between the
two groups of patients were found in the synovial fluid
concentrations of COMP and GAG. However, serumconcentrations in synovial fluid and serum were determined
by two different methods; an in-house RIA using polyclonal
rabbit antibodies3 and a commercial ELISA using both
monoclonal and polyclonal antibodies (Metra Biosys-
tems)15. The two assays and the normal YKL-40 levels in
serum and synovial fluid are described in detail else-
where3,15,17. The source of the YKL-40 antigen used for
standards and production of antibodies in both methods
were purified from the conditioned medium of the human
osteosarcoma cell line MG63. However, the methods used
to calibrate the standards were different. The concentration
of the amino-terminal propeptide of type III procollagen was
determined by RIA23. The concentrations in synovial fluid
and serum of cartilage oligomeric matrix protein (COMP)
and sulfated glucosaminoglycans (GAG) were determined
by Wieslab (Lund, Sweden)24,25. The concentrations in
synovial fluid of myeloperoxidase26, lactoferrin27, neu-
trophil gelatinase associated lipocalin (NGAL)28 and
human cathelicidin (hCAP-18)29 were determined by
ELISA. Due to restricted amounts of serum and synovial
fluid available, incomplete number of measurements
occurred in some of the variables analysed.
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RA patients (P<0.01) (Table I).SYNOVIAL FLUID YKL-40 LEVELS IN RELATION TO HISTOLOGICAL
ASSESSMENT OF SYNOVIAL INFLAMMATION
Highest levels of YKL-40 in synovial fluid were found in
knee joints from patients with RA and moderate to severe
degree of synovial inflammation (median 6300 g/L) and
the levels were higher (P=0.054) compared to patients with
OA and moderate to severe synovial inflammation
(3400 g/L) (Table II and Fig. 2). Patients with RA and none
to slight synovial inflammation had higher levels of YKL-40
in synovial fluid compared to OA patients with none to slight
synovitis (median 4200 g/L vs 2450 g/L, P=0.026). Simi-
lar results were found when the ELISA method was used to
measure YKL-40. There was a trend towards higher SF
YKL-40 levels in RA patients with moderate to severe
synovial inflammation compared to those with none to
slight synovitis; however, the difference was not significant
(P=0.096).IMMUNOHISTOCHEMICAL STAINING OF YKL-40 IN SYNOVIAL
MEMBRANE IN RELATION TO SYNOVIAL INFLAMMATION AND
SYNOVIAL FLUID YKL-40 LEVELS
Positive staining for CD68 antigen was observed in cells
of the synovial lining and in mononuclear cells in the stroma
of the synovial membrane in patients with RA and OA, and
some of these cells were also positive for YKL-40 antigen[Fig. 3(A)]. The number of YKL-40 positive cells was related
with the degree of synovial inflammation. A severely
inflamed synovial membrane had a higher number of
YKL-40 positive cells compared to a less inflamed synovial
membrane. No difference was observed in the staining
pattern of synovial membranes of RA and OA patients. The
score of YKL-40 positive cells in the synovium gained from
0 (no positive cells) to 2 (25–75% positive cells) (Table III).
No sections had positive YKL-40 staining in all cells.
YKL-40 positive cells were found in 29% of the sections
with none to slight synovial inflammation and in 70% of the
sections with moderate to severe synovial inflammation.
The level of YKL-40 in synovial fluid was related to the
score of YKL-40 positive cells in the synovial membrane
(Fig. 4) (Kruskal–Wallis test, P=0.0156, N=22) with a
significant difference (Dunn’s method, P<0.05) between
synovial membranes with the higher (score=2) and the
lower (score=0) number of YKL-40 positive cells.Table I
Patient characteristics in the cross-sectional and the longitudinal study of arthritic knee joints
Cross-sectional study Longitudinal study
RA Normal values
RA OA
Age 66 (29–77)20*** 74 (50–85)39 58 (19–78)18
Number of swollen joints—total 3 (0–18)19*** 0 (0–3)35 3 (1–30)
Number of swollen joints—large 2 (0–6)19*** 0 (0–3)35 2.5 (1–10)
Number of swollen joints—small 0 (0–13)19*** 0 (0)35 0 (0–25)
ESR, mm/h 44 (3–95)20*** 12 (2–92)35 47 (2–105) <20
Serum CRP, nmol/L 246 (30–1413)20*** 89 (30–419)37 327 (29–777) <90
Serum YKL-40 (RIA), g/L 296 (55–920)19* 130 (56–1290)31 276 (104–540) <208 (Ref. 17)
Serum YKL-40 (ELISA), g/L 87 (20–218)12 73 (26–565)31 <95 (Ref. 15)
Serum COMP, mg/L 0.9 (0.6–1.3)14** 1.2 (0.7–1.7)22
Serum PIIINP, g/L 4.5 (1.5–8.4)19** 3.4 (1.4–6.0)31 <3.5
Synovial inflammation, 0–1 1 (0–1)20*** 0 (0–1)39
MRI/synovial membrane volume, cm3 69 (21–93)10* 36 (8–79)21
MRI/joint effusion volume, cm3 40 (4–232)10 21 (0–119)21
SF YKL-40 (RIA), g/L 4890(910–13800)20*** 2700 (351–6000)39 <1350 (Ref. 17)
SF YKL-40 (ELISA), g/L 2120 (485–6850)14** 1190 (274–2600)29 <402 (Ref. 15)
SF PIIINP, g/L 3230 (600–6700)19*** 960 (240–3310)37
SF COMP, mg/L 7.2 (3.1–22.1)18 9.2 (3.9–20.5)34
SF GAG, mg/L 42 (10–132)16 42 (3–79)33
Ratio SF/serum YKL-40 (RIA) 20 (2–67)19 13 (3–55)31
Ratio SF/serum YKL-40 (ELISA) 16 (8–112)39 15 (3–56)33
Ratio SF YKL-40 (RIA)/SF COMP 548 (122–2721)17** 247 (38–939)34
Ratio SF YKL-40 (RIA)/SF GAG 156 (15–540)16* 63 (8–530)33
Ratio SF YKL-40 (ELISA)/SF COMP 295 (34–991)14* 144 (19.7–440)29
Ratio SF YKL-40 (ELISA)/SF GAG 75 (11–234)13 34 (10–200)28
Values are given as median and rangesnumber of patients. CRP=C-reactive protein; ESR=erythrocyte sedimentation rate; PIIINP=amino
terminale propeptide of type III procollagen; COMP=cartilage oligomeric matrix protein; GAG=glycosaminoglycans; MRI=magnetic
resonance imaging. SF=synovial fluid; synovial inflammation (0=none/slight, 1=moderate/severe). *=P<0.05; **=P<0.01; ***=P<0.001 vs
patients with OA tested by the Mann–Whitney U-test.SYNOVIAL FLUID YKL-40 LEVELS IN RELATION TO THE SYNOVIAL
MEMBRANE AND JOINT EFFUSION VOLUMES DETERMINED BY MRI
The concentration of YKL-40 in synovial fluid was signifi-
cantly correlated with the MRI-determined volumes of the
synovial membrane (rho=0.64, P<0.001, N=31) (Fig. 5) as
well as the joint effusion volumes (rho=0.59; P<0.001,
N=31) in patients with RA and OA. A significant correlation
was found between serum PIIINP and the volume of the
synovial membrane (rho=0.39, P<0.05) and of the joint
effusion determined by MRI (rho=0.33; P=0.07). Synovial
fluid levels of COMP, GAG and the markers of different
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volume of the synovial membrane and joint effusion.knees (<1350 g/L).IMMUNOHISTOCHEMICAL STAINING OF YKL-40 IN ARTICULAR
CARTILAGE IN RELATION TO HISTOPATHOLOGICAL CARTILAGE
CHANGES
All the arthritic cartilage sections had considerable his-
topathological changes, including surface fibrillation or fis-
sures and/or clones or clusters. In the pannus-invaded
cartilage [Fig. 3(B)] a prominent YKL-40 staining was
shown in the cytoplasm of the different cells types present
in the pannus, and the extracellular matrix also exhibited
some staining [Fig. 3(C)]. We did not attempt to differentiate
between the YKL-40 staining in the different cell types. The
extracellular matrix in the underlying cartilage was YKL-40
negative around both YKL-40 positive and negative
chondrocytes [Fig. 3(C)]. The cartilage from patients with
RA exhibited frequently prominent fibrous pannus and
clusters/clones [Fig. 3(C)] compared with cartilage from OA
patients [Fig. 3(D)]. YKL-40 was found in the cytoplasm of
the chondrocytes [Fig. 3(E)] but not in the extracellular
matrix, except in areas of pannus-invaded cartilage. Treat-
ment with protease, trypsin or hyaluronidase prior to the
immunohistochemical staining did not reveal any overt
additional YKL-40 staining of the extracellular cartilage
matrix or in the chondrocytes. YKL-40 positive chondro-
cytes were observed in all layers of the cartilage. Most of
the sections included non-intact residual cartilage with only
the middle and/or the deep layer left, and no differences
in the staining pattern between the different layers could be
identified. Chondrocytes located in clusters/clones and in
areas of excessive surface fibrillation showed a similar
pattern of YKL-40 staining as found in isolated chondro-
cytes and chondrocytes in other areas of the same section.
No difference was found between the YKL-40 staining
pattern in articular cartilage in RA and OA patients. Most
cartilage sections had a score of 1 (1–25% positive
chondrocytes). Seven sections had a YKL-40 score of 2(25–75% positive chondrocytes) (three sections from RA
patients and four sections from OA patients), and no
sections had a score of 3. Arthritic knees without YKL-40
staining in chondrocytes were not found. There was no
difference in respect of topographic site in the knee joint
and the YKL-40 staining (Table IV).IMMUNOHISTOCHEMICAL STAINING OF YKL-40 IN ARTICULAR
CARTILAGE IN RELATION TO SYNOVIAL INFLAMMATION AND
SYNOVIAL FLUID YKL-40 LEVELS
YKL-40 staining in chondrocytes from knees with mod-
erate to severe synovial inflammation was similar to the
YKL-40 staining in chondrocytes from knees with none to
slight synovial inflammation. Two of the knees from which
cartilage specimens were obtained were graded with mod-
erate to severe synovial inflammation (both knees were
from RA patients) and these knees had high SF YKL-40
levels (7830 and 13 800 g/L). Two knees were graded
with no signs of synovial inflammation (both from OA
patients) but the YKL-40 concentration in the synovial fluid
was higher (1991 and 4200 g/L) than the level in normal
17Table II
The synovial fluid concentration of the biochemical markers in relation to the degree of synovial inflammation of the knee joint in patients with
RA and OA
RA OA
Synovial inflammation None/slight Moderate/severe None/slight Moderate/severe
Number of patients 7 13 33 6
YKL-40 (RIA), g/L 4200 (1450–5900)7 6300 (910–13800)13 2450 (351–4700)33 3400 (1400–6000)6
YKL-40 (ELISA), g/L 1865 (485–2360)6 3340 (1540–6850)8 1180 (274–2470)23 1795 (835–2600)6
PIIINP, g/L 3230 (650–6540)7 3085 (600–6700)12 940 (240–3310)31 1135 (670–2530)6
COMP, mg/L 13.6 (5.1–22.1)7 6.8 (3.1–20.5)11* 9.3 (4.5–20.5)28 8.1 (3.9–9.5)6
GAG, mg/L 65 (10–132)7 30 (18–49)9* 58 (3–79)27 22 (13–60)6
Ratio YKL-40/COMP 222 (123–1059)7 1186 (193–2721)10** 230 (38–640)28 551 (148–939)6
Ratio YKL-40/GAG 55 (15–540)7 228 (97–387)9* 56 (8–530)27 115 (48–462)6*
Ratio YKL-40 (ELISA)/COMP 110 (34–459)6 518 (123–991)8* 125 (20–440)23 259 (88–419)6*
Ratio YKL-40 (ELISA)/GAG 20 (11–234)6 91 (62–228)7* 30 (10–163)22 84 (29–200)6*
NGAL, g/L 66 (19–116)3 377 (12–591)5 30 (17–47)18 61 (29–92)2
Lactoferrin, g/L 831(30–10110)6 771 (228–1345)4 112 (30–7106)25 596 (94–6232)4
h-CAP 18, g/L 1678 (127–7305)5 2034 (461–3453)4 128 (49–1619)31 494 (115–879)4
MPO, g/L 33 (14–208)4 219 (51–461)6 60 (16–647)26 59 (52–410)3
Values are given as medians and rangesnumber of patients. RIA=radioimmunoassay; ELISA=enzyme linked immunosorbent assay;
PIIINP=amino terminal propeptide of type III procollagen; COMP=cartilage oligomeric matrix protein; GAG=glycosaminoglycans; markers
of neutrophil activation: NGAL=neutrophil gelatinase associated lipocalin; lactoferrin; cathelicidin h-CAP 18; MPO=myeloperoxidase.
*=P<0.05; **=P<0.01; ***=P<0.001 vs none/slight synovial inflammation tested by the Mann–Whitney U-test.SYNOVIAL FLUID YKL-40 LEVELS IN RELATION TO BIOCHEMICAL
MARKERS OF SYNOVIAL INFLAMMATION, CARTILAGE
DEGRADATION AND ACTIVATED NEUTROPHILS
In patients with RA or OA, no significant correlation
existed between SF levels of YKL-40 as compared with
PIIINP, COMP, GAG or the markers of the specific granules
in neutrophils. The concentrations of PIIINP, COMP, GAG,
lactoferrin, NGAL and hCAP-18 (located to the specific
granules as YKL-40) were not different in the synovial fluid
from patients with moderate to severe synovial inflamma-
tion and patients with none to slight synovial inflammation
(Table II), neither in patients with RA nor OA.
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fluid present in the knee joints we also calculated the
synovial fluid results as ratios. The median values of the
ratios of YKL-40/COMP and YKL-40/GAG were signifi-
cantly higher in RA knees with moderate to severe synovial
inflammation (Table II) compared with RA knees with none
to slight synovial inflammation (P=0.024 and P=0.025,
respectively), whereas significant differences between the
groups in patients with OA were only found for the ratio of
YKL-40/GAG (P=0.045) and not for the ratio YKL-40/
COMP.RELATIONSHIP BETWEEN YKL-40 LEVELS IN SYNOVIAL FLUID AND
SERUM
YKL-40 in synovial fluid correlated significantly with
serum YKL-40 (rho=0.46, P=0.05, N=19) in patients with
RA as well as in patients with OA (rho=0.50, P=0.004,
N=31). The median ratio of YKL-40 in synovial fluid and
serum was 19.8 in patients with RA and 12.8 in patients
with OA (Table I). Furthermore, significant correlations were
found between SF YKL-40 and the ESR (rho=0.68,
P=0.008) and serum CRP (rho=0.62, P=0.003) in patientsCHANGES IN SERUM YKL-40 AFTER INTRAARTICULAR
CORTICOSTEROID
Serum YKL-40 was initially 276 g/L and significantly
higher in the RA patients (P<0.001) compared with the
value of healthy controls17. Following intraarticular corticos-
teroid injection clinical remission occurred. Serum YKL-40
decreased significantly after only 1 day (median 180 g/L,
P=0.03). After 7 and 14 days serum YKL-40 was
decreased by 15.7% (P=0.017) and 18.4% (P=0.025)
(Table V). However, when a separate test (random coef-
ficient regression model) for an initial effect of glucocorti-
coid injection and for a trend in the subsequent
development (taking into account a possible variation of
these effects between persons), the initial effect of gluco-
corticoid was found to be significant (P=0.0018), but the
subsequent trend with sustained decrease at day 7 and 14
with return to baseline at day 30 was non-significant
(P=0.127). Eight patients had a clinical relapse during the
next 6 months and these patients had an increase in serum
YKL-40 at the time of relapse (350 g/L) compared with the
previous value (224 g/L, P<0.05). Serum PIIINP was also
decreased 1 day after glucocorticoid injection (Table V).
After 7 days the serum PIIINP concentrations were also
significantly decreased, but after 14 days the values were
not different from the baseline values. Significant
decreases in serum CRP were seen at day 1, 7, and 14
and in ESR at day 7 and 14 after glucocorticoid injection
(Table V).Fig. 2. Synovial fluid concentrations of YKL-40 (determined by
radioimmunoassay (RIA) and ELISA, respectively), COMP, and
GAG in relation to the degree of synovial inflammation determined
by histological criteria. =patients with RA and =patients
with OA. COMP=cartilage oligomeric matrix protein; GAG=
glycosaminoglycans. The hatched areas represent the normal
values of the different parameters. Normal values of COMP and
GAG were not available.
Discussion
The present study demonstrated high concentrations of
YKL-40 in synovial fluid of the knee joint of patients with RA
and OA. By immunohistochemical methods we demon-
strated the presence of YKL-40 in synovial cells of the
inflamed synovial membrane with a positive relation
between the number of YKL-40 positive cells and the
severity of the synovial inflammation. In addition, the MRI-
determined volume of the synovial membrane and joint
effusion, an estimation of the degree of synovial inflamma-
tion, was also related to the levels of YKL-40 in synovial
fluid. Others have reported that activated macrophages
secrete YKL-40 in vitro6–8,12,13 and in-situ hybridization
studies have demonstrated YKL-40 expression in macro-
phages located in the synovial membrane of patients with
RA6. Our demonstration of macrophage CD68 positive
cells in the inflamed synovial membrane, also positive for
YKL-40 antigen, is consistent with the macrophage as a
source of secretion of YKL-40 into the synovial fluid.
Furthermore, in RA patients a positive relation between the
degree of synovial inflammation and the ratios of YKL-40/
COMP in synovial fluid was shown, with highest synovial
fluid levels of YKL-40 in knees with the highest degree of
synovial inflammation. The findings provide evidence that
YKL-40 is released from the synovial membrane underwith RA, but not in patients with OA. Serum YKL-40
correlated with serum CRP (rho=0.56, P=0.02) in patients
with RA. The serum and synovial fluid levels of YKL-40
were highest using the in-house RIA. Highly significant
correlations were found between both the serum values
and the synovial fluid levels of YKL-40 when the results of
the two methods were compared (synovial fluid: rho=0.77,
P<0.001 and serum: rho=0.90, P<0.001).
210 B. Volck: YKL-40 in arthritic knee jointsFig. 3. Representative light micrographs of immunohistochemical staining of YKL-40 in synovial membranes and cartilage from knee joints
of patients with RA and OA. (a) A moderately to severely inflamed synovial membrane from a patient with OA. Some of the macrophage
CD68 positive cells (brown/red color) were also positive for YKL-40 antigen (dark blue/violet color) as illustrated in the double stained section
from a patient with OA and moderate to severe synovial inflammation. The arrow indicates a double stained cell (bar=40 m). (b) A pannus
from a patient with RA illustrating YKL-40 positive staining of the cells. The arrowhead indicates an YKL-40 positive mononuclear cell. The
arrow indicates disintegrated cartilage (bar=100 m). (c) Pannus-covered cartilage section rich in clones (arrow) from location no. 10 (see
Fig. 1) of the knee joint of a patient with RA, illustrating YKL-40 staining in the cytoplasm of the chondrocytes. No staining is detectable in
the cartilage matrix (bar=100 m). However, the pannus as well as the pannus-invaded cartilage shows diffuse YKL-40 staining in the
extracellular matrix. (d) Osteoarthritic cartilage section from location no. 7 (see Fig. 1), illustrating YKL-40 positive chondrocytes through the
superficial zone (sf) and middle zone (mz) of the cartilage. YKL-40 positive chondrocytes are also found in the deep zone of the cartilage (not
shown) (bar=100 m). (e) A high magnification of a chondrocyte from (D) showing the granular distribution of YKL-40 in the cytoplasm of the
chondrocyte (bar=40 m).pathophysiological conditions. However, the high amounts
of YKL-40 detectable in the synovial fluid may also origi-
nate from other sources, including chondrocytes and
activated neutrophils.
In the articular cartilage from the arthritic knee joints
YKL-40 was discovered in the cytoplasm of the chondro-
cytes, in accordance with two recent studies on cartilage
from osteoarthritic hip joints10,11. It is known that chondro-
cytes secrete YKL-40 in vitro1,5, and one would expect to
find YKL-40 in the articular extracellular matrix. However,
YKL-40 staining in the extracellular matrix of cartilage was
only found in areas of pannus-invaded cartilage. Enzyme
digestion of the cartilage sections prior to the immunohis-
tochemical staining did not expose YKL-40 staining in the
extracellular matrix. The presence of YKL-40 in the pericel-
lular matrix or extracellular matrix can not be excluded,
since YKL-40 may be bound in a way that prevents its
detection or the protein may be present in too low a
concentration to be detected by our antibody. Unfortu-nately, we did not have the opportunity to obtain ‘normal’
cartilage from non-arthritic knee joints. In a recent study of
arthritic and normal cartilage of hip joints10 we showed that
chondrocytes from normal cartilage were, in general,
YKL-40 negative. The finding is in accordance with the
studies of Hakala et al.1 and Connor et al.11, demonstrating
no YKL-40 mRNA expression by normal human chondro-
cytes. A few of the studied arthritic knees showed no signs
of synovial inflammation; nevertheless, the synovial fluid
YKL-40 level was higher compared to normal knee joints.
The observations may indicate that chondrocytes of the
arthritic cartilage contributes to the high level of YKL-40 in
synovial fluid of the knee joints from patients with RA and
OA. The findings are in accordance with our previous
reported hypothesis that YKL-40 may play a role in
cartilage remodeling in arthritic joints10.
COMP, a non-collagenous glycoprotein belonging to the
heterogeneous family of thrombospondin30 was originally
isolated from cartilage. COMP levels in synovial fluid and
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Number of YKL-40 positive cells in the synovial membrane (evaluated as a score) from knee joints of patients with
rheumatoid arthritis and osteoarthritis
Score 0 1 2 3
Sections from patients with RA (N=10) 20% 20% 60% 0%
Sections from patients with OA (N=14) 79% 14% 7% 0%
Sections from patients with none/slight synovitis (N=9) 71% 21% 7% 0%
Sections from patients with moderate/severe synovitis (N=15) 30% 10% 60% 0%
Values are given as percentage of the number of sections with a given score in relation to the total of number
of sections evaluated. Score 0=all cells negative (0%); score 1=few cells positive (1–25%); score 2=a
considerable number of cells positive (25–75%); score 3=most/all cells positive (75–100%).Fig. 4. YKL-40 concentrations in synovial fluid in knee joints of
patients with RA () and OA () in relation to the number of
YKL-40 positive cells in the synovial membrane. 0=all cells nega-
tive; 1=few cells positive (1–25% positive cells); 2=a considerable
number of positive cells (25–75% positive cells). A significant
relation was found between the number of YKL-40 positive cells in
the synovial membrane and the YKL-40 concentration in the
synovial fluid (Kruskal–Wallis test: P=0.0156). The significant
difference was revealed between SF YKL-40 and synovial mem-
branes with a score=2 and a score=0 (Dunn’s method, P<0.05).
The horizontal bars show the median values of each group.Fig. 5. Synovial fluid concentrations of YKL-40 in relation to
the volume of the synovial membrane determined by magnetic
resonance imaging.serum may be related to cartilage damage31–33. However,
COMP cannot be regarded as a cartilage-specific protein,
since it is also found in tendon, meniscus, cruciate
ligaments34–36 and is secreted in vitro by synovial fibro-
blasts35. In-situ hybridization has shown expression of
COMP mRNA in the synovial sublining cells of inflamed
synovium from patients with RA.35 In contrast to YKL-40,
the COMP expression was not detected in CD68 positive
cells of the synovial membrane, but restricted to fibro-
blasts.35 In the present study serum, but not SF COMP
levels were significantly higher in patients with OA com-
pared with patients with RA. A quantitative analysis of the
amount of articular cartilage was not performed in our
study. However, the inverse relation between the synovial
fluid levels of YKL-40 and COMP and GAG may indicate
that the release of YKL-40 from the cartilage is inferior to
the release of YKL-40 from the synovium. We found a
significant difference between the SF ratios YKL-40/COMP
in RA patients with moderate to severe synovial inflamma-
tion compared to RA patients with none to slight synovial
inflammation. A trend towards higher concentrations ofYKL-40 in synovial fluid in patients with RA and moderate to
severe synovial inflammation compared with none to slight
inflammation was found. However, the difference was not
significant. The significant difference in the ratio YKL-40/
COMP between the two groups of synovial inflammation in
RA patients may be due to the YKL-40 levels corrected for
the influence of variable amounts of synovial fluid present
in the different joints by estimating the values of connective
tissue markers as ratios.
Neutrophils are important in the pathogenesis of RA37,38.
These cells comprise more than 90% of the cells in the
synovial space of joints from patients with active RA and
have a turnover rate of more than a billion cells per day in
an inflamed knee joint39. The neutrophils are also present
at the cartilage–pannus junction and can release proteases
and biologically destructive oxidative products that can
damage cartilage and fibrous tissue, resulting in joint
damage39–42. YKL-40 is present in the specific granules of
neutrophils and is exocytosed in vitro upon activation14. In
the present study we found that hCAP-18, another protein
exocytosed from the specific granules of neutrophils,
showed a trend towards highest levels in the patients with
moderate to severe synovial inflammation of the knee joint,
but there were only a few patients in each group (N=4 and
N=5) and no statistical difference was achieved. These
observations and the fact that the different organelles of the
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Topographical distribution of YKL-40 positive chondrocytes in cartilage from arthritic knee joints (RA and OA)
Location no. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Median score 16 0.58 07 0.58 08 17 0.58 17 17 18 17 17 17 08 0.58 0.56
Range 0–2 0–1 0–1 0–1 0–1 0–1 0–2 0–2 0–2 0–2 0–1 0–2 0–1 0–1 0–2 0–1
Values are given as median scoresnumber of sections evaluated and ranges. The location numbers are presenting the topographical locations of
the knee joint for the cartilage samples (see Fig. 1).Table V
The changes in four different serological variables of synovial inflammation following intra-articular glucocorticoid injection (GCC) in knee
joints of patients with RA
Time of
intraarticular GGC
Day 1 Day 7 Day 14 Day 30
Serum YKL-40 (g/L) 276 (104–480)18 180 (108–485)17* 164 (84–414)15* 172 (54–470)15** 179 (56–500)14
Serum PIIINP (g/L) 4.2 (2.2–8.6)14 2.9 (1.1–5.1)13*** 2.9 (1.7–5.0)13** 3.7 (2.1–8.3)11 3.6 (2.3–11.9)10
Serum CRP (nmol/L) 329 (29–1016)17 210 (29–1547)15* 64 (29–327)15*** 166 (29–520)14*** 126 (29–1616)15
ESR (mm/h) 46 (2–105)17 46 (2–130)15 30 (2–84)13** 28 (8–100)14* 41 (4–109)15
Values are given as medians and rangesnumber of patients. The data shown are only from patients who did not suffer from relapse of knee joint
synovitis in the 30 days time period. *=P<0.05; **=P<0.01; and ***=P<0.001 vs value at time of intraarticular glucocorticoid injection by
Wilcoxon signed rank test.neutrophils are exocytosed in a strict hierarchy41, suggest
that some of the YKL-40 present in the synovial fluid from
patients with moderate to severe synovitis originates from
neutrophils in the joint. However, the ratios between
YKL-40 and the other granule proteins of neutrophils in the
synovial fluid were all higher as compared with the ratios
that were calculated by results from a recent study where
the granule proteins were mobilized from neutrophils in
suspension in response to stimulation14. This finding indi-
cates that synovial fluid YKL-40 also originates from
sources other than neutrophils.
In the present study we used two different methods3,15 to
determine the YKL-40 levels in synovial fluid and serum.
We do not know if the two antibodies used in the ELISA
method recognize the same epitope on the YKL-40 antigen
as recognized by the polyclonal antibody used in our
in-house YKL-40 RIA. We found a good correlation
between YKL-40 determined by the two methods. There
was, however, a difference between the exact levels of
YKL-40. This may be explained by differences in the
calculation of the standard used in the two assays.
RA is a polyarticular disease. Correlations between con-
centrations of components in synovial fluid and serum
therefore reflect changes in the global amount of synovial
fluid and synovial tissue. The positive correlations between
serum YKL-40 and YKL-40 in the synovial fluid of the knee
joints accords with the dominating knee joint synovitis in the
present study and the quantitative dominance of synovial
tissue in the knee joint. The ratios of YKL-40 in synovial
fluid to serum did not differ between patients with RA and
OA reflecting the non-specific nature of joint inflammation.
The synovial fluid concentrations of YKL-40 are determined
by the release of YKL-40 to the synovial fluid, as well as by
the clearance of YKL-40 from the joint cavity, which is
unknown so far.
Intraarticular glucocorticoid injection was followed by a
decrease in clinical signs of synovitis and a decrease of
serum YKL-40. Similarly, a clinical relapse of the knee
synovitis was accompanied by an increase in serum
YKL-40. The findings demonstrate that local synovitis-derived YKL-40 influences serum YKL-40. Similar results
were found for serum PIIINP though the values returned to
baseline earlier than the values of YKL-40 did. The mech-
anism by which glucocorticoid influences YKL-40 produc-
tion is unknown. The changes in serum YKL-40 were
positively correlated with changes in the serum levels of
PIIINP, CRP and ESR, though following a somewhat differ-
ent course. When the synovial membrane is inflamed, the
synthesis as well as degradation rate of type III collagen is
increased43. PIIINP is a marker of type III collagen syn-
thesis and is synthesized and secreted by synovial cells44.
We found high concentrations of SF PIIINP in patients with
RA, which probably reflect an increased turnover of type III
collagen in the inflamed synovium. The positive correlation
between YKL-40 and PIIINP supports the assumption that
YKL-40 in part originates from the inflamed synovial mem-
brane. CRP and ESR, the gold standards of biochemical
assessment of the disease activity in RA, are produced in
the liver by the hepatocytes and are thus an indirect
measure of joint inflammation. By contrast, serum YKL-40
is a more direct measure of joint inflammation. Future
studies may reveal the potential of serum YKL-40
to provide new information on disease activity and
pathophysiology of the synovitis in RA.
In conclusion, our study showed that YKL-40 was
detected in the inflamed synovial membrane and the
number of YKL-40 positive cells was related with the
degree of synovial inflammation. Apart from YKL-40
derived from the synovial membrane, YKL-40 derived from
articular cartilage and neutrophils in the synovial fluid may
contribute to SF YKL-40. A relationship exists between
YKL-40 in serum and synovial fluid with approximately
15-fold higher levels in synovial fluid. Intraarticular gluco-
corticoid injection, inducing remission in joint inflammation,
was followed by a decrease in serum YKL-40. The findings
are consistent with a local release of YKL-40 in the arthritic
joint influencing serum YKL-40. Assessment of serum
YKL-40 may provide new and direct information on the
local disease activity as well as on the pathophysiological
processes in the arthritic joint.
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